You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In May, Kurin sued Magnolia for allegedly making false claims about the efficacy and regulatory status of its Steripath blood culture collection system.
The firm's nanotechnology-enabled, AI-based, machine learning tool identifies biomarkers in blood samples and produces results in 10 to 30 seconds.
The company said Q2 sales increased 11 percent on a currency-neutral basis, driven by growth in both its Life Science and Clinical Diagnostics segments.
The study showed the test had a high negative predictive value, but critics cited a lack of data on cost and outcomes.
The researchers detected an average of 56 possible environmental organic acids present in each subject and confirmed the presence of six of them.
The system combines proprietary dry slide technology with digital imaging capabilities and the ability to run two separate lab tests simultaneously.
Having achieved CE marking, the new OLO system has launched in Europe and non-US countries, while the company is conducting studies necessary for US FDA clearance.
The Early Sepsis Indicator is intended to provide clinicians information about sepsis and the risk of developing sepsis in patients in acute care settings.
The study found that for some patients the standard practice of performing a second confirmatory blood test is not necessary, which could streamline care.
Kurin alleges Magnolia has made false claims about its technology’s false-positive rates and contamination rates, as well as misleading claims about FDA clearance.